Table of Contents Author Guidelines Submit a Manuscript
Journal of Nanomaterials
Volume 2013, Article ID 863951, 11 pages
http://dx.doi.org/10.1155/2013/863951
Review Article

Nanoparticle-Based Drug Delivery for Therapy of Lung Cancer: Progress and Challenges

1Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
2Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
3Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
4The Graduate Program in Biomedical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA

Received 26 August 2013; Accepted 28 October 2013

Academic Editor: Haifeng Chen

Copyright © 2013 Anish Babu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. S. Ramalingam, T. K. Owonikoko, and F. R. Khuri, “Lung cancer: new biological insights and recent therapeutic advances,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 91–112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. L. C. Pronk, G. Stoter, and J. Verweij, “Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects,” Cancer Treatment Reviews, vol. 21, no. 5, pp. 463–478, 1995. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Lu, M. Liong, J. I. Zink, and F. Tamanoi, “Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs,” Small, vol. 3, no. 8, pp. 1341–1346, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Kumar, S. K. Sahoo, K. Padhee et al., “Review on solubility enhancement techniques for hydrophobic drugs,” International Journal of Comprehensive Pharmacy, vol. 3, no. 3, pp. 1–7, 2011. View at Google Scholar
  5. P. Agostinis, K. Berg, K. A. Cengel et al., “Photodynamic therapy of cancer: an update,” CA Cancer Journal for Clinicians, vol. 61, no. 4, pp. 250–281, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Babu, J. Periasamy, A. Gunasekaran et al., “Polyethylene glycol-modified gelatin/polylactic acid nanoparticles for enhanced photodynamic efficacy of a hypocrellin derivative in vitro,” Journal of Biomedical Nanotechnology, vol. 9, no. 2, pp. 177–192, 2013. View at Google Scholar
  7. M. Dougan and G. Dranoff, “Immune therapy for cancer,” Annual Review of Immunology, vol. 27, pp. 83–117, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. A. Kay, “State-of-the-art gene-based therapies: the road ahead,” Nature Reviews Genetics, vol. 12, no. 5, pp. 316–328, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Giacca and S. Zacchigna, “Virus-mediated gene delivery for human gene therapy,” Journal of Controlled Release, vol. 161, no. 2, pp. 377–388, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Nayak and R. W. Herzog, “Progress and prospects: immune responses to viral vectors,” Gene Therapy, vol. 17, no. 3, pp. 295–304, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. H. Grossman and S. E. McNeil, “Nanotechnology in cancer medicine,” Physics Today, vol. 65, pp. 38–42, 2012. View at Google Scholar
  12. A. Z. Wang, R. Langer, and O. C. Farokhzad, “Nanoparticle delivery of cancer drugs,” Annual Review of Medicine, vol. 63, pp. 185–198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Ahmad, “Gene delivery by nanoparticles offers cancer hope,” The Lancet Oncology, vol. 3, no. 8, p. 451, 2002. View at Google Scholar · View at Scopus
  14. R. Ramesh, “Nanoparticle-mediated gene delivery to the lung,” Methods in Molecular Biology, vol. 434, pp. 301–331, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Yuan, Y. Lv, Y. Yao et al., “Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: a retrospective clinical study,” Thoracic Cancer, vol. 3, no. 4, pp. 341–347, 2012. View at Google Scholar
  16. R. M. Schiffelers, J. M. Metselaar, M. H. A. M. Fens, A. P. C. A. Janssen, G. Molema, and G. Storm, “Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice,” Neoplasia, vol. 7, no. 2, pp. 118–127, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Simões, A. Filipe, H. Faneca et al., “Cationic liposomes for gene delivery,” Expert Opinion on Drug Delivery, vol. 2, no. 2, pp. 237–254, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Adamina, U. Guller, L. Bracci, M. Heberer, G. C. Spagnoli, and R. Schumacher, “Clinical applications of virosomes in cancer immunotherapy,” Expert Opinion on Biological Therapy, vol. 6, no. 11, pp. 1113–1121, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. L. H. Lindner, M. E. Eichhorn, H. Eibl et al., “Novel temperature-sensitive liposomes with prolonged circulation time,” Clinical Cancer Research, vol. 10, no. 6, pp. 2168–2178, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Krishnan, L. Deschatelets, F. C. Stark, K. Gurnani, and G. D. Sprott, “Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8+ T cell responses,” Clinical and Developmental Immunology, vol. 2010, Article ID 578432, 13 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent, “Cisplatin nephrotoxicity: a review,” American Journal of the Medical Sciences, vol. 334, no. 2, pp. 115–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Boulikas, “Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts,” Oncology Reports, vol. 12, no. 1, pp. 3–12, 2004. View at Google Scholar · View at Scopus
  23. P. Devarajan, R. Tarabishi, J. Mishra et al., “Low renal toxicity of lipoplatin compared to cisplatin in animals,” Anticancer Research, vol. 24, no. 4, pp. 2193–2200, 2004. View at Google Scholar · View at Scopus
  24. “Liposomal cisplatin (Nanoplatin) for advanced non-small cell lung cancer—first line (2012),” http://www.hsc.nihr.ac.uk/topics/liposomal-cisplatin-nanoplatin-for-advanced-non-sm/.
  25. X. Wang, J. Zhou, Y. Wang et al., “A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions,” European Journal of Cancer, vol. 46, no. 8, pp. 1474–1480, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Zhou, W. Y. Zhao, X. Ma et al., “The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer,” Biomaterials, vol. 34, no. 14, pp. 3626–3638, 2013. View at Google Scholar
  27. S. Koudelka and J. Turánek, “Liposomal paclitaxel formulations,” Journal of Control Release, vol. 163, no. 3, pp. 322–334, 2012. View at Google Scholar
  28. G. P. Stathopoulos, D. Antoniou, J. Dimitroulis et al., “Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial,” Annals of Oncology, vol. 21, no. 11, pp. 2227–2232, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. S. North and C. Butts, “Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers,” Expert Review of Vaccines, vol. 4, no. 3, pp. 249–257, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. G. T. Wurz, A. M. Gutierrez, B. E. Greenberg et al., “Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model,” Journal of Translational Medicine, vol. 11, no. 1, pp. 64–77, 2013. View at Google Scholar
  31. Y.-L. Wu, K. Park, R. A. Soo et al., “INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer,” BMC Cancer, vol. 11, article 430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Lu, D. J. Stewart, J. J. Lee et al., “Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans,” Plos One, vol. 7, no. 4, Article ID e34833, 2012. View at Google Scholar
  33. S. H. Choi, S.-E. Jin, M.-K. Lee et al., “Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 68, no. 3, pp. 545–554, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. K. H. Bae, J. Y. Lee, S. H. Lee, T. G. Park, and Y. S. Nam, “Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging,” Advanced Healthcare Materials, vol. 2, no. 4, pp. 576–584, 2013. View at Google Scholar
  35. A. Z. Wang, K. Yuet, L. Zhang et al., “ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation,” Nanomedicine, vol. 5, no. 3, pp. 361–368, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Jung, S. J. Park, H. K. Chung et al., “Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancer,” International Journal of Radiation Oncololgy Biology Physics, vol. 84, pp. e77–e83, 2012. View at Google Scholar
  37. D.-W. Kim, S.-Y. Kim, H.-K. Kim et al., “Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer,” Annals of Oncology, vol. 18, no. 12, pp. 2009–2014, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. “A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer,” 2013, http://clinicaltrials.gov/show/NCT01770795.
  39. L. Jiang, X. Li, L. Liu, and Q. Zhang, “Thiolated chitosan-modified PLA-PCL-TPGS nanoparticles for oral chemotherapy of lung cancer,” Nanoscale Research Letters, vol. 8, no. 1, p. 66, 2013. View at Google Scholar
  40. T. Zhao, H. Chen, L. Yang et al., “DDAB-modified TPGS-b-(PCL-ran-PGA) Nanoparticles as oral anticancer drug carrier for lung cancer chemotherapy,” Nano, vol. 8, no. 2, Article ID 1350014, 10 pages, 2013. View at Google Scholar
  41. A. Mehrotra, R. C. Nagarwal, and J. K. Pandit, “Lomustine loaded chitosan nanoparticles: characterization and in-vitro cytotoxicity on human lung cancer cell line L132,” Chemical and Pharmaceutical Bulletin, vol. 59, no. 3, pp. 315–320, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Liu, O. V. Khullar, A. P. Griset et al., “The pax-eNP placed at the time of surgical resection delayed local tumor recurrence and modestly prolonged survival in a murine Lewis lung carcinoma recurrence model,” Annals of Thoracic Surger, vol. 91, no. 4, pp. 1077–1083, 2011. View at Google Scholar
  43. R. Yang, S.-G. Yang, W.-S. Shim et al., “Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates,” Journal of Pharmaceutical Sciences, vol. 98, no. 3, pp. 970–984, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Tahara, H. Yamamoto, N. Hirashima, and Y. Kawashima, “Chitosan-modified poly(d,l-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 74, no. 3, pp. 421–426, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. C.-L. Tseng, T.-W. Wang, G.-C. Dong et al., “Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting,” Biomaterials, vol. 28, no. 27, pp. 3996–4005, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. C.-L. Tseng, W.-Y. Su, K.-C. Yen, K.-C. Yang, and F.-H. Lin, “The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation,” Biomaterials, vol. 30, no. 20, pp. 3476–3485, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Karthikeyan, N. R. Prasad, A. Ganamani, and E. Balamurugan, “Anticancer activity of resveratrol-loaded gelatin nanoparticles on NCI-H460 non-small cell lung cancer cells,” Biomedicine and Preventve Nutrition, vol. 3, no. 1, pp. 64–73, 2013. View at Google Scholar
  48. J. Liu, J. Liu, L. Chu et al., “Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer,” International Journal of Nanomedicine, vol. 6, no. 1, pp. 59–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. G. M. Ryan, L. M. Kaminskas, B. D. Kelly, D. J. Owen, M. P. McIntosh, and C. J. H. Porter, “Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent,” Molecular Pharmaceutics, vol. 10, no. 8, pp. 2986–2995, 2013. View at Google Scholar
  50. “Dendrimers improve anticancer efficacy in lung metastasis model,” 2013, http://www.starpharma.com/news/150.
  51. R. Yang, S.-G. Yang, W.-S. Shim et al., “Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates,” Journal of Pharmaceutical Sciences, vol. 98, no. 3, pp. 970–984, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. W. P. Su, F. Y. Cheng, D. B. Shieh, C. S. Yeh, and W. C. Su, “PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells,” International Journal of Nanomedicine, vol. 7, pp. 4269–4283, 2012. View at Google Scholar
  53. N. Karra, T. Nassar, A. N. Ripin et al., “Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model,” Small, 2013. View at Publisher · View at Google Scholar
  54. J. Conde, G. Doria, and P. Baptista, “Noble metal nanoparticles applications in cancer,” Journal of Drug Delivery, vol. 2012, Article ID 751075, 12 pages, 2012. View at Publisher · View at Google Scholar
  55. G. Peng, U. Tisch, O. Adams et al., “Diagnosing lung cancer in exhaled breath using gold nanoparticles,” Nature Nanotechnology, vol. 4, no. 10, pp. 669–673, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J.-A. A. Ho, H.-C. Chang, N.-Y. Shih et al., “Diagnostic detection of human lung cancer-associated antigen using a gold nanoparticle-based electrochemical immunosensor,” Analytical Chemistry, vol. 82, no. 14, pp. 5944–5950, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. O. Barash, N. Peled, U. Tisch, P. A. Bunn Jr., F. R. Hirsch, and H. Haick, “Classification of lung cancer histology by gold nanoparticle sensors,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 8, no. 5, pp. 580–589, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. Y.-H. Chen, C.-Y. Tsai, P.-Y. Huang et al., “Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model,” Molecular Pharmaceutics, vol. 4, no. 5, pp. 713–722, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Yokoyama, J. Tam, S. Kuroda et al., “Egfr-targeted hybrid plasmonic magnetic nanoparticles synergistically induce autophagy and apoptosis in non-small cell lung cancer cells,” PLoS ONE, vol. 6, no. 11, Article ID e25507, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. L. L. Ma, J. O. Tam, B. W. Willsey et al., “Selective targeting of antibody conjugated multifunctional nanoclusters (nanoroses) to epidermal growth factor receptors in cancer cells,” Langmuir, vol. 27, no. 12, pp. 7681–7690, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Lkhagvadulam, J. H. Kim, I. Yoon, and Y. K. Shim, “Size-dependent photodynamic activity of gold nanoparticles conjugate of water soluble purpurin-18-N-methyl-D-glucamine,” BioMed Research International, vol. 2013, Article ID 720579, 10 pages, 2013. View at Publisher · View at Google Scholar
  62. R. Govender, A. Phulukdaree, R. M. Gengan, K. Anand, and A. A. Chuturgoon, “Silver nanoparticles of Albizia adianthifolia: the induction of apoptosis in human lung carcinoma cell line,” Journal of Nanobiotechnology, vol. 11, no. 5, pp. 1477–3155, 2013. View at Google Scholar
  63. W. G. Zhou and W. Wang, “Synthesis of silver nanoparticles and their antiproliferation,” The Oriental Journal of Chemistry, vol. 28, no. 2, pp. 651–655, 2012. View at Google Scholar
  64. R. Foldbjerg, D. A. Dang, and H. Autrup, “Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549,” Archives of Toxicology, vol. 85, no. 7, pp. 743–750, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Sadhukha, T. S. Wiedmann, and J. Panyam, “Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy,” Biomaterials, vol. 34, no. 21, pp. 5163–5171, 2013. View at Google Scholar
  66. Y. Wang, Y. Zhang, Z. Du, M. Wu, and G. Zhang, “Detection of micrometastases in lung cancer with magnetic nanoparticles and quantum dots,” International Journal of Nanomedicine, vol. 7, pp. 2315–2324, 2012. View at Google Scholar
  67. K. Li, B. Chen, L. Xu et al., “Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo,” International Journal of Nanomedicine, vol. 8, pp. 1867–1877, 2013. View at Google Scholar
  68. W. Sun, N. Fang, B. G. Trewyn et al., “Endocytosis of a single mesoporous silica nanoparticle into a human lung cancer cell observed by differential interference contrast microscopy,” Analytical and Bioanalytical Chemistry, vol. 391, no. 6, pp. 2119–2125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. A. J. Di Pasqua, M. L. Miller, X. Lu, L. Peng, and M. Jay, “Tumor accumulation of neutron-activatable holmium-containing mesoporous silica nanoparticles in an orthotopic non-small cell lung cancer,” Inorgica Chimca Acta, vol. 393, no. 1, pp. 334–336, 2012. View at Google Scholar
  70. O. Taratula, O. B. Garbuzenko, A. M. Chen, and T. Minko, “Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA,” Journal of Drug Targeting, vol. 19, no. 10, pp. 900–914, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Sundarraj, “EGFR antibody conjugated mesoporous silica nanoparticles for cytosolic phospholipase A2α targeted nonsmall lung cancer therapy,” Journal of Cell Science and Therapy, vol. 3, no. 7, 2012. View at Google Scholar
  72. H. Maeda, “The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting,” Advances in Enzyme Regulation, vol. 41, pp. 189–207, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. N. Dinauer, S. Balthasar, C. Weber, J. Kreuter, K. Langer, and H. Von Briesen, “Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes,” Biomaterials, vol. 26, no. 29, pp. 5898–5906, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Schreier, L. Gagné, T. Bock et al., “Physicochemical properties and in vitro toxicity of cationic liposome cDNA complexes,” Pharmaceutica Acta Helvetiae, vol. 72, no. 4, pp. 215–223, 1997. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Bao, S. Mitragotri, and S. Tong, “Multifunctional nanoparticles for drug delivery and molecular imaging,” Annual Review of Biomedical Engineering, vol. 15, pp. 253–282, 2013. View at Google Scholar
  76. R. Wang, P. S. Billone, and W. M. Mullet, “Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials,” Journal of Nanomaterials, vol. 2013, Article ID 629681, 12 pages, 2013. View at Publisher · View at Google Scholar
  77. A. F. Hubbs, R. R. Mercer, S. A. Benkovic et al., “Nanotoxicology—a pathologist's perspective,” Toxicologic Pathology, vol. 39, no. 2, pp. 301–324, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. J. McCarthy, I. Inkielewicz-Stepmiak, J. J. Corbalan, and M. W. Radomski, “Mechanisms of toxicity of amorphous silica nanoparticles on human using submucosal cells in vitro: protective effects of fisetin,” Chemical Research in Toxicology, vol. 25, no. 10, pp. 2227–2235, 2012. View at Google Scholar
  79. B. Trouiller, R. Reliene, A. Westbrook, P. Solaimani, and R. H. Schiestl, “Titanium dioxide nanoparticles induce DNA damage and genetic instability in vivo in mice,” Cancer Research, vol. 69, no. 22, pp. 8784–8789, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Make, L. Wang, and Y. Rojanasakul, “Mechanisms of nanoparticle-induced oxidative stress and toxicity,” BioMed Research International, vol. 2013, Article ID 942916, 15 pages, 2013. View at Publisher · View at Google Scholar
  81. D. F. Emerich and C. G. Thanos, “The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis,” Biomolecular Engineering, vol. 23, no. 4, pp. 171–184, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. S. M. Moghimi, A. C. Hunter, and J. C. Murray, “Long-circulating and target-specific nanoparticles: theory to practice,” Pharmacological Reviews, vol. 53, no. 2, pp. 283–318, 2001. View at Google Scholar · View at Scopus
  83. M. A. Dobrovolskaia, P. Aggarwal, J. B. Hall, and S. E. McNeil, “Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution,” Molecular Pharmaceutics, vol. 5, no. 4, pp. 487–495, 2008. View at Publisher · View at Google Scholar · View at Scopus